• Surgery-Colo-Rectal
• Surgical Oncology

The main clinical and research interests of Phillip Fleshner, MD, are directed towards optimizing outcomes and techniques in the surgical management of Crohn's disease and ulcerative colitis. Fleshner has written numerous articles for peer-reviewed publications, including the Journal of the American College of Surgeons, Diseases of the Colon and Rectum, Gut, American Journal of Surgery and Annals of Surgery.

• Medical School: Albert Einstein College of Medicine, New York, 1984
• Fellowship: Massachusetts General Hospital, 1988
• Residency: Mount Sinai Medical Center, 1990
• Fellowship: Lahey Clinic, 1991

• Cancer Institute (Samuel Oschin Comprehensive Cancer Institute)
• Anorectal Disorders
• Inflammatory Bowel Disease J-Pouch Program
• Department of Surgery
• Colorectal Surgery
• Cancer
• Surgery
• Inflammatory Bowel and Immunobiology Research Institute

• Northwest Society of Colon and Rectal Surgeons Award, American Society of Cataract and Refractive Surgery Annual Meeting, 2013
• Golden Apple Teaching Award, Department of Surgery, Cedars-Sinai, 1994, 1995, 2002
• American Society of Colon and Rectal Surgeons Traveling Fellow Award, 1994
• Harry E. Bacon Foundation Award, 1993
• Arthur H. Aufses Sr. Prize in Surgery Award, 1990

Click here for a list of peer-reviewed publications.

• Norman JM, Handley SA, Baldridge MT, Droit L, Liu CY, Keller BC, Kambal A, Monaco CL, Zhao G, Fleshner P, et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell. 2015;60(3):447-460.
• Zaghiyan K, McGovern D, Fleshner P. Should biologic agents be stopped before surgery for inflammatory bowel disease? Expert Rev Gastroenterol Hepatol. 2015 Mar;9(3):269-272.
• Lau C, Dubinsky M, Melmed G, Vasiliauskas E, Berel D, McGovern D, Ippoliti A, Shih D, Targan S, Fleshner P. The impact of preoperative serum anti-TNFα therapy levels on early postoperative outcomes in inflammatory bowel disease. Ann Surg. 2015;261(3):487-496.